Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CPA3 | P15088 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531678 | 1.00 | HPGD (0.45) | HPGDNPC1RAB9AMMEMEN1 | |
| SCHEMBL532696 | 1.00 | HPGD (0.45) | HPGDNPC1RAB9AMMEMEN1 | |
| SCHEMBL531859 | 1.00 | HPGD (0.45) | HPGDNPC1RAB9AMMEMEN1 | |
| SCHEMBL1594483 | 0.84 | PPARG (0.40) | MMEMEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL1594480 | 0.84 | PPARG (0.40) | MMEMEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL14660173 | 0.84 | TRPA1 (0.40) | HPGDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL5930180 | 0.84 | HPGD (0.39) | HPGDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL5930175 | 0.84 | HPGD (0.39) | HPGDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL16163310 | 0.84 | TRPA1 (0.40) | HPGDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL21144939 | 0.83 | MAOB (0.43) | NPC1RAB9AMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893765-B1 | A PROCESS FOR PREPARING (2R,3S)-1,2-EPOXY-3-(PROTECTED)AMINO-4-SUBSTITUTED BUTANE AND INTERMEDIATES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2011-11-30 | — | — | EP | claimed |
| EP-1893765-A1 | A PROCESS FOR PREPARING (2R,3S)-1,2-EPOXY-3-(PROTECTED)AMINO-4-SUBSTITUTED BUTANE AND INTERMEDIATES THEREOF | Brystol-Myers Squibb Company (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2006127180-A1 | A PROCESS FOR PREPARING (2R,3S)-1,2-EPOXY-3-(PROTECTED)AMINO-4-SUBSTITUTED BUTANE AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060270012-A1 | Process for preparing (2R,3S)-1,2-epoxy-3-(protected)amino-4-substituted butane and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-30 | — | — | US | claimed |
| US-8119389-B2 | Rhodococcus erythropolis strain | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| EP-1893765-B1 | A PROCESS FOR PREPARING (2R,3S)-1,2-EPOXY-3-(PROTECTED)AMINO-4-SUBSTITUTED BUTANE AND INTERMEDIATES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20090286303-A1 | PROCESS FOR PREPARING (2R,3S)-1,2-EPOXY-3-(PROTECTED) AMINO-4-SUBSTITUTED BUTANE AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-19 | — | — | US | disclosed |
| US-7582468-B2 | Process for preparing (2R,3S)-1,2-epoxy-3-(protected)amino-4-substituted butane and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1893765-A1 | A PROCESS FOR PREPARING (2R,3S)-1,2-EPOXY-3-(PROTECTED)AMINO-4-SUBSTITUTED BUTANE AND INTERMEDIATES THEREOF | Brystol-Myers Squibb Company (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| WO-2006127180-A1 | A PROCESS FOR PREPARING (2R,3S)-1,2-EPOXY-3-(PROTECTED)AMINO-4-SUBSTITUTED BUTANE AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270012-A1 | Process for preparing (2R,3S)-1,2-epoxy-3-(protected)amino-4-substituted butane and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | HPGD 3430/4885NPC1 3573/4885RAB9A 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.